Allgenesis has been Granted Australian Patent for Multi-Tyrosine Kinase Inhibitor in Ophthalmic Suspension and its use for Treating Ocular Surface Diseases
Allgenesis Biotherapeutics Inc. has been Granted U.S. Patent for Pterygium Treatment Using Multi-Tyrosine Kinase Inhibitor in Ophthalmic Suspension
2018-12-28Allgenesis Receives Notice of Acceptance of Australian Patent for Fusion Protein of VEGF Trap and Disintegrin
2019-02-13January 3rd, 2019
Allgenesis Biotherapeutics Inc., a Taiwan based specialty pharmaceutical company focused on developing novel ophthalmologic drugs, announced today that it received an Australian patent covering multi-tyrosine kinase inhibitor in ophthalmic suspension and its use to treat ocular surface diseases.
“Allgenesis continues to explore treatment of ocular surface diseases using multi-tyrosine kinase inhibitor in either micro- or nano-suspension for 505(B)2 projects in its development pipeline and this patent affords us a greater protection for our IP portfolio in Australia,” said Dr. Madhu Cherukury, Chief Executive Officer of Allgenesis Biotherapeutics Inc. “Together with the pterygium treatment patent previously granted in U.S., the ophthalmic drug product we are developing is now better protected by our patents in various geographical regions.
The newly issued patent provides coverage of multi-tyrosine kinase inhibitor in the ophthalmic suspension and its use to treat ocular surface diseases in Australia up to 2036.
About Allgenesis
Allgenesis is a clinical stage biopharmaceutical company based in Taipei, Taiwan. The company is focused on research and development of novel medicines for the treatment of eye diseases. Current projects in the pipeline include AG-73305, a potential blockbuster drug for the treatment of DME, wAMD, and other retinal diseases. AG-73305 is in the CMC stage of the development with IND filing before 1Q2021. AG-86893, a drug for the treatment of Pterygium or better-known as surfer’s eye, is in Phase 2a clinical trial in Australia with FPE in 4Q2018.
About AG-86893
AG-86893 is a topical ocular eye drop reformulation of a marketed oral drug, a multi-tyrosine kinase inhibitor targeting receptors of growth factors such as VEGF, PDGF and FGF. AG-86893 is being developed for the treatment of pterygium, following a 505(B)(2) pathway. Currently, there is no approved treatment for pterygium other than surgery. Clinical Phase 2a trial for AG-86893 is being conducted for pterygium patients in Australia with FPE in 4Q2018.